Searched for
METSERA
Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
- Why is PFE stock falling today despite beating Pfizer's earnings estimates? Key factors investors are watchingPFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Decl...
- Weight-loss treatment: How has obesity medicine market become battleground for pharma giants like Pfizer, AstraZeneca, Eli Lilly?Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...
- S&P 500, Nasdaq and Dow Jones see big rise as heavyweight tech stocks witness rebound: Galecto sees 250% gain, Sonder Holdings plunges; check top gainers and losers on November 10 and here’s how top indices performedWall Street saw a sharp rise on Monday, November 10, 2025. Major US indices like the S&P 500 and Nasdaq surged. This rally was powered by N...
- S&P 500, Dow Jones, and Nasdaq futures flat after big gains from AI companies boost Wall Street; here’s how key indices performedWall Street experienced a strong start to the week, with major indices like the S&P 500, Nasdaq, and Dow Jones closing sharply higher. This...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- Metsera accepts Pfizer's $10 billion bid in ongoing M&A battleMetsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per sh...
- US stock market today: Nasdaq dropped 1.9%, S&P 500 lost 1.1%, Dow slipped 0.8% — What led to Wall Street turning red and why Tesla, Nvidia, Amazon, and Palantir sankUS stock market fell hard today as AI hype cracked. The Nasdaq plunged 1.9%, the S&P 500 slipped 1.1%, and the Dow lost 0.8%. Tesla slid 3....
- Pfizer weighs sweeter offer for Metsera after Judge blocks bid to halt Novo Nordisk’s $10 billion takeoverPfizer is increasing its offer for Metsera. This comes after a judge rejected Pfizer's attempt to stop rival Novo Nordisk's bid. Pfizer's d...
- Pfizer, Novo Nordisk escalate bidding war for obesity drug developer MetseraA fierce bidding war is underway for Metsera, an obesity drug developer. Novo Nordisk has made a $10 billion offer, which Metsera considers...
- Pfizer sues Metsera, Novo Nordisk over rival obesity drug bidPfizer sued Metsera and Novo Nordisk, alleging Metsera breached its merger agreement by deeming Novo's $8.5 billion bid superior. Pfizer se...
- PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisitionPfizer Inc. (NYSE: PFE) experienced a significant uptick in its stock price following two major announcements on September 30, 2025. Presid...
- S&P 500, Nasdaq subdued after rally, Trump's visa crackdown weighsThe S&P 500 and Nasdaq experienced a subdued session on Monday, despite recent record highs, influenced by uncertainty surrounding potentia...
- Pfizer PFE stock, Metsera MTSR stock: Pfizer, Metsera share prices jump as deal worth over $7 billion gets thumbs upStock Market boom for both companies' shares came as Pfizer said on Monday it would acquire drug developer Metsera in a deal valued at up t...
- US stock market today: Dow, S&P 500, Nasdaq Pull Back from record highs as Gold hits fresh all-time peakUS stocks fell slightly as investors waited for Fed speeches and key inflation data. Gold hit a record high while Bitcoin and other cryptoc...
- Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera: ReportPfizer is close to acquiring Metsera, an anti-obesity drug developer. The deal could be worth $7.3 billion. Pfizer will pay $47.50 per shar...
- US co Amneal plans units in India for weight-loss drugsAmneal Pharmaceuticals is set to invest $150-200 million over four to five years to build a manufacturing facility in Ahmedabad for weight ...
Load More
